Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Canopy Growth (CGC) will acquire all issued and outstanding shares of MTL Cannabis in a transaction valued at approximately $125 million equity and $179 million TEV. Consideration is 0.32 Canopy Growth share plus $0.144 cash per MTL share, implying ~$0.91 per MTL share and a 45% premium to MTL’s 20-day VWAP as of December 12, 2025. MTL reported $84M TTM revenue, 51% gross margin (before fair value adjustments) and $11M operating cash flow for the trailing twelve months ended September 30, 2025. Canopy expects ~$10M of run-rate synergies within 18 months and closing is expected before end of February 2026, subject to court, shareholder and regulatory approvals.
Canopy Growth (Nasdaq: CGC) announced on December 4, 2025 the national launch of Claybourne Gassers, a new line of All‑in‑One (AIO) liquid diamond vapes in Canada. The collection includes three 0.95g SKUs — Infused Grape Gasolina (Indica), Infused Blue Dream (Sativa) and Infused Lemon Cherry G (Hybrid) — each with 92–98% THC, a digital display, variable voltage, anti‑burn/anti‑clog tech and a rechargeable USB‑C palm format. Canopy also launched Claybourne Frosted Flyers 8‑pack infused pre‑rolls (8x0.35g) with 33–36% THC. Products are available at licensed retail stores and select online retailers across Canada, including Spectrum Therapeutics for registered medical consumers.
Canopy Growth (Nasdaq: CGC) expanded its Spectrum Therapeutics medical portfolio in Australia by launching new softgel capsules available through authorized prescribers.
The new formats are Spectrum Yellow Cannabis Oil Softgels (CBD 20mg), Spectrum Red Cannabis Oil Softgels (THC 10mg), and Spectrum Blue Cannabis Oil Softgels (Balanced THC 2.5mg : CBD 3.75mg), which complement existing Spectrum oils and flower and other Tweed, 7ACRES, and TWD flower products in Australia.
Company leadership said the softgels increase patient and prescriber choice and support the growth of its international medical business in a maturing Australian market.
Canopy Growth (NASDAQ:CGC) reported Q2 FY2026 results for the quarter ended September 30, 2025, showing sequential and year‑over‑year improvement across several metrics.
Key highlights: consolidated net revenue $67MM (+6% YoY); cannabis revenue $51MM (+12% YoY); Canada adult‑use $24MM (+30% YoY); Canada medical $22MM (+17% YoY). Cash and cash equivalents were $298MM, exceeding debt by $70MM, resolving prior going‑concern doubts. Q2 operating loss improved to $17MM (‑63% YoY) and Adjusted EBITDA loss narrowed to $3MM. The company reported margin headwinds from lower international sales and inventory provisions but captured $21MM of annualized cost savings since March 1, 2025.
Canopy Growth (NASDAQ:CGC, TSX:WEED) will release its second quarter fiscal 2026 financial results for the period ended September 30, 2025 before markets open on November 7, 2025.
Management will host a live audio webcast with Luc Mongeau, CEO, and Tom Stewart, CFO on November 7, 2025 at 10:00 AM ET. A live webcast link and a replay accessible through February 5, 2026 at 11:59 PM ET are provided.
Canopy Growth (Nasdaq: CGC) reported voting results from its Annual General and Special Meeting reconvened on October 10, 2025. All matters in the company proxy were approved by the requisite votes.
Key items approved include election of all director nominees (each elected to serve until the next annual meeting), re-appointment of PKF O’Connor Davies as auditors for the fiscal year ending March 31, 2026, an advisory vote on named executive officer compensation, and an amendment authorizing a potential share consolidation that the board may implement within 12 months or let lapse.
Canopy Growth (Nasdaq: CGC) announced that its DOJA facility in Kelowna, BC is now operating exclusively as a medical cultivation site supporting the company's Spectrum Therapeutics portfolio as of October 8, 2025. The site will produce small-batch, BC-grown craft cannabis under the DOJA brand that will be available only to registered Spectrum Therapeutics medical patients, including veterans. The facility operates under a new micro-cultivation license and has been upgraded to deliver consistent, high-quality flower and support product development within Spectrum's medical lineup.
JP Brand Advisors and Canopy USA announced a strategic partnership on October 7, 2025 to expand U.S. distribution of Wana Wellness hemp-based beverages and gummies. The agreement assigns JP Brand Advisors to support distributor management and strategic account growth while leveraging Canopy USA's cannabis-market distribution footprint. The partnership targets growth in the non-alcoholic, functional and hemp-infused beverage segment amid rising retailer and distributor interest and greater regulatory clarity in key markets.
Canopy Growth (NASDAQ:CGC) has announced the adjournment of its Annual General and Special Meeting of Shareholders due to insufficient quorum. The meeting, originally scheduled for September 26, 2025, has been rescheduled to October 10, 2025 at 1:00 PM ET via live webcast.
The company requires 33 1/3% of outstanding shares to be represented for quorum, as per NASDAQ listing requirements. Shareholders of record as of August 1, 2025 are eligible to vote, and the voting deadline has been extended to October 8, 2025. The company has retained Laurel Hill Advisory Group to assist shareholders with the voting process.
Canopy Growth (NASDAQ:CGC) has extended the proxy voting deadline for its upcoming Annual General and Special Meeting to September 26, 2025 at 9:00 AM ET. The Meeting will be held the same day at 1:00 PM ET via live audio webcast. The extension aims to ensure a quorum of 33 1/3% of outstanding shares, required by NASDAQ listing rules.
CEO Luc Mongeau indicated they are close to achieving quorum and encouraged remaining shareholders to participate. The company has retained Laurel Hill Advisory Group to assist shareholders with voting, which can be done online, by phone, or through various platforms depending on where shares are held.